in female MA users. In both sexes, individuals with MA dependence were more likely to have greater daily (p<0.001) and monthly MA use (p<0.001) during the periods of their heaviest use as well as having more lifetime episodes of MA use (p<0.001). With respect to logistic regression analysis, nicotine dependence (in males; OR=4.1, 95% CI=2.4-7.0, p<0.001 and in females; OR=2.4, 95% CI=1.3-4.4, p=0.007), severe MA-use (e.g., > 1000 episodes of use in their lifetime; in males; OR=3.5, 95% CI=1.9-6.4, p<0.001 and in females; OR=5.9, 95% CI=3.1-11.4, p<0.001), using MA 15 or more days per month during the heaviest use period (in males; OR=5.1, 95% CI=2.8-9.1, p<0.001 and in females; OR=3.6, 95% CI=1.9-6.9, p<0.001)) were predictors of MA dependence in both sexes. However, comorbid ASPD predicted MA-dependence in males only (OR=3.7, 95% CI=1.6-8.6, p=0.002) (Table 4).
